HomeCompareCYCCP vs GBDC

CYCCP vs GBDC: Dividend Comparison 2026

CYCCP yields 5.94% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.83M in total portfolio value
10 years
CYCCP
CYCCP
● Live price
5.94%
Share price
$5.05
Annual div
$0.30
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$0.61
Full CYCCP calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — CYCCP vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYCCPGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYCCP + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYCCP pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYCCP
Annual income on $10K today (after 15% tax)
$504.95/yr
After 10yr DRIP, annual income (after tax)
$0.52/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,983,123.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYCCP + GBDC for your $10,000?

CYCCP: 50%GBDC: 50%
100% GBDC50/50100% CYCCP
Portfolio after 10yr
$10.44M
Annual income
$8,225,367.23/yr
Blended yield
78.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

CYCCP
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Altman Z
-74.5
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYCCP buys
0
GBDC buys
0
No recent congressional trades found for CYCCP or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYCCPGBDC
Forward yield5.94%11.86%
Annual dividend / share$0.30$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%51.1%
Portfolio after 10y$20.7K$20.85M
Annual income after 10y$0.61$16,450,733.83
Total dividends collected$604.00$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: CYCCP vs GBDC ($10,000, DRIP)

YearCYCCP PortfolioCYCCP Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$10,997$297.03$12,492$1,791.70$1.5KGBDC
2$11,919$152.64$16,527$3,160.58$4.6KGBDC
3$12,831$77.31$23,588$5,904.90$10.8KGBDC
4$13,768$38.89$37,141$11,901.65$23.4KGBDC
5$14,751$19.50$66,205$26,463.38$51.5KGBDC
6$15,794$9.76$137,452$66,612.65$121.7KGBDC
7$16,904$4.88$342,372$195,298.53$325.5KGBDC
8$18,090$2.44$1,053,292$686,954.33$1.04MGBDC
9$19,358$1.22$4,111,439$2,984,416.95$4.09MGBDC
10$20,713$0.61$20,849,974$16,450,733.83$20.83MGBDC

CYCCP vs GBDC: Complete Analysis 2026

CYCCPStock

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Full CYCCP Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this CYCCP vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYCCP vs SCHDCYCCP vs JEPICYCCP vs OCYCCP vs KOCYCCP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.